Evidence map›Paper›PMID 31475169›Full record

ArticleAnnals of translational medicine2019

Impact of prior cancer on outcomes in nasopharyngeal carcinoma.

Huaqiang Zhou, Yaxiong Zhang, Jiaqing Liu, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Gang Chen, Shen Zhao, Jiayi Shen, Wei Xian and 5 more

Abstract read
In one paragraph

Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Prior cancer history predicts the worse survival of patients with nasopharyngeal carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Huaqiang ZhouDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yaxiong ZhangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Jiaqing LiuZhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
Wenfeng FangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yunpeng YangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Shaodong HongDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Gang ChenDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Shen ZhaoDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Jiayi ShenZhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
Wei XianZhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
Zhonghan ZhangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Xi ChenDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Hongyun ZhaoDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Yan HuangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Li ZhangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrior cancer is a common exclusion criterion in nasopharyngeal carcinoma (NPC) trials. However, whether a prior cancer diagnosis affects trial outcomes is still unknown. We aimed to determine the impact of prior cancer on survival in NPC patients.

methodsWe identified patients diagnosed with NPC between 2004 and 2009 in the Surveillance, Epidemiology, and End Results (SEER) database. Variables were compared by chi-squared test and

resultsAmong 3,131 eligible NPC patients, 349 (11.15%) patients had a history of prior cancer. The Kaplan-Meier curves did not show a statistically significantly different OS (P=0.19). Subgroup analyses stratified by timing of prior cancer and AJCC TNM stage of index cancer displayed the same tendency: prior cancer did not adversely affect OS compared to patients without prior cancer (P>0.05). Furthermore, in propensity score-adjusted COX models analysis, patients with prior cancer had the same/non-inferior OS [hazard ratio (HR) =1.12; 95% confidence interval, 0.88 to 1.42].

conclusionsAmong patients with NPC, prior cancer does not convey an adverse effect on clinical outcomes, regardless of the timing of prior cancer and AJCC TNM stage of index cancer. Broader inclusion trial criteria could be adopted in NPC patients with a history of prior cancer. However, further studies are still needed to confirm this conclusion.

Indexed as

clinical trialnasopharyngeal carcinoma (NPC)Prior cancerSurveillance, Epidemiology, and End Results (SEER)survival

Identifiers

PMID31475169
PMCPMC6694232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.